Cleaning Verification Before Sterilization: Turning a Hidden Risk Into a Controlled Step

In a reprocessing workflow, sterilization is a visible control point: the load is identified, the cycle is monitored, and the results are reviewed before release. However, sterilization assurance begins earlier. Reusable devices must be thoroughly cleaned before disinfection or sterilization because residual organic or inorganic material can interfere with the effectiveness of those processes.[1][2] Inadequate rinsing can also leave material on the device that should have been removed during cleaning.[1]

For CSSD and sterile-processing teams, the practical question is how documented procedures can establish that cleaning has produced a device suitable for the facility’s reprocessing and sterilization process. Cleaning verification is therefore related to, but distinct from, sterilization monitoring.

Why cleaning belongs in sterilization assurance

Cleaning removes foreign material and organic soil from device surfaces. CDC guidance identifies thorough cleaning as necessary before sterilization because residual organic and inorganic material can interfere with process effectiveness.[1] Soil that dries or becomes heat-fixed can be more difficult to remove and may reduce the margin of safety of subsequent disinfection or sterilization.[1][2]

The concern is not limited to readily visible surfaces. Hinges, serrations, narrow lumens, valves, sleeves, joints, and other complex features can retain debris that is difficult to detect during routine inspection.[3] A device may therefore appear clean externally while remaining inadequately cleaned internally.

What a practical cleaning-verification program should control

1. Point-of-use treatment

Cleaning quality can be compromised before an instrument reaches the decontamination area. Blood and tissue that dry on an instrument are more difficult to remove.[1] Point-of-use practices should address prompt removal of gross soil, keeping instruments appropriately moist when required by the device or detergent instructions, and safe transport to the reprocessing area.[1][4]

These controls should be defined in a procedure that assigns responsibilities to the clinical area and the CSSD. Recurring delays, unsuitable transport conditions, or inconsistent use of a pretreatment product may indicate a process issue requiring investigation.

2. Device-specific cleaning instructions

Reusable devices should be cleaned according to the current manufacturer’s instructions for use. Instructions should be accessible, controlled, and sufficiently detailed for the device’s design. Relevant details may include disassembly, brush dimensions, flushing connections, detergent use, water quality, temperature, contact time, rinsing, and drying, when specified by the applicable instructions.[4]

FDA information identifies long or narrow channels, rough internal surfaces, hinges, O-rings, valves, and areas that cannot be disassembled as features that may retain soil.[3] These features should be reflected in work instructions, inspection points, staff training, and quality audits.

3. Visual inspection—with defined limitations

Visual inspection remains an important part of the workflow, but it is not a complete cleaning-verification method. It can identify obvious soil, damage, corrosion, moisture, or an assembly problem. It may not detect small amounts of residue or contamination within a lumen or another difficult-to-see feature.[5]

To make visual inspection more consistent, facilities can define adequate lighting, magnification where appropriate, inspection of difficult-to-see features, and clear accept-or-reject criteria. When a device cannot be adequately inspected in its assembled state, the inspection method should follow the applicable reprocessing instructions, including disassembly when required.

4. Supplementary cleaning-monitoring methods

Cleaning-monitoring literature describes methods that assess residual soil or other indicators of cleaning performance, including approaches directed at protein, hemoglobin, carbohydrate, or other targets.[5] These methods can support process monitoring and quality improvement, but their usefulness depends on the device, the target soil, the sampling approach, the test method, and the purpose defined by the facility.[5]

ATP-based methods require particular caution. Their applicability to reusable medical devices is device-, method-, and facility-specific. An ATP result should not be treated as a universal device-release criterion without documented evidence that the method is appropriate for the intended use.[5]

Before using a supplementary method, the facility should define:

• which devices, trays, process steps, or equipment will be sampled;
• why the selected method is relevant to the soil or device feature of concern;
• how samples will be collected consistently, including locations and timing;
• how the method’s intended use and limitations will be assessed;
• what constitutes an alert or investigation trigger under the facility’s procedure;
• how results will be documented and trended; and
• what corrective action follows an unfavorable result.

These are facility quality-management decisions rather than universal acceptance rules established by the cited sources. FDA guidance on validation methods and labeling primarily addresses manufacturers’ validation of reusable-device reprocessing instructions. It does not establish a CSSD release requirement or a universal threshold for residual soil, ATP, protein, hemoglobin, carbohydrate, or another test.[4]

Accordingly, a supplementary result should support investigation and process improvement within a documented local procedure. It should not, by itself, be presented as proof that a device is safe or unsafe for release. The facility’s procedure should explain how an alert or unfavorable result is evaluated in the relevant decision.

How to respond to an unfavorable or alert result

An unfavorable, alert, or questionable cleaning result should be handled under an approved facility procedure rather than treated as an isolated laboratory event. The device should be identified and managed according to that procedure, which may include holding it from further use or release, assessing the result, and repeating reprocessing when appropriate. CDC guidance requires thorough cleaning before sterilization, while the cleaning-monitoring literature describes monitoring as part of a broader quality-improvement approach.[1][5]

An investigation may examine:

• time from point of use to cleaning;
• whether soil was allowed to dry;
• correct device disassembly and flushing;
• brushes, connectors, detergents, and equipment settings;
• washer-disinfector or ultrasonic-cleaner performance, where applicable;
• operator training and adherence to the current IFU;
• the sampling location, collection method, and test method; and
• whether similar devices or process steps may be affected.

The scope and disposition are facility risk-management decisions. A single unfavorable result should not automatically be characterized as invalidating an entire sterilized load, and it should not automatically be assumed to affect only one device. The facility should determine the relevant scope using its documented procedure, the reliability of the result, the device or device family, the sampling location, the process step, the time period, the equipment involved, and available records.

Repeated unfavorable results may indicate that a device is difficult to clean under actual conditions, that the procedure is not sufficiently detailed, or that the selected equipment is unsuitable. FDA guidance identifies clinically relevant soil, worst-case soiling, residual-soil measurement, and device features that affect cleaning as considerations in manufacturer reprocessing validation.[3][4] These considerations can help a facility frame questions for procedure review and manufacturer consultation without replacing the manufacturer’s instructions or establishing a CSSD acceptance threshold.

What this means for sterilization release

Cleaning verification and sterilization monitoring address different process questions. CDC guidance describes sterilization as dependent on adequate prior cleaning, and cleaning-monitoring literature describes separate approaches for assessing cleaning performance.[1][2][5] On that basis, a sterilizer cycle record or sterilization indicator result should not be interpreted as evidence that a device was adequately cleaned; this is a facility quality-management interpretation of the distinction between the two controls, not a universal release rule stated by the cited sources.

Release procedures should therefore keep cleaning acceptance, packaging inspection, sterilization monitoring, and load documentation as related but distinct controls. If a cleaning concern is identified before or after sterilization, the affected device or potentially affected group should be managed according to the facility’s documented hold, investigation, reprocessing, and corrective-action procedures. The scope should be determined from the evidence and the facility’s risk assessment, not inferred solely from an alert result or from inclusion in the same load.

Practical implementation checklist

• Maintain current, accessible device-specific cleaning instructions.
• Identify complex devices and features requiring special inspection or supplementary monitoring.
• Define point-of-use treatment and transport expectations with clinical departments.
• Use visual inspection consistently while documenting its limitations.
• Select supplementary tests for a defined quality-improvement purpose and document sampling, method limitations, interpretation rules, and facility action thresholds.
• Recognize that FDA Guidance [4] primarily addresses manufacturer validation of reprocessing instructions and does not establish a CSSD release requirement or universal acceptance threshold.
• Trend results by device family, operator, shift, location, and equipment when useful.
• Escalate repeated unfavorable results to education, procedure review, equipment assessment, or manufacturer consultation.
• Do not use sterilization-monitoring results as the sole basis for resolving an unresolved cleaning concern.

Limitations

Cleaning-verification methods differ in target soils, sensitivity, sampling requirements, and interpretation.[5] A negative result does not prove the complete absence of all contamination, and an unfavorable result does not by itself identify the root cause or determine the scope of affected items. Local procedures should be based on the device manufacturer’s instructions, the capabilities of the facility, applicable regulations and standards, and a documented quality-risk assessment.

Educational disclaimer: This article is for professional education and does not replace device-specific manufacturer instructions, validated facility procedures, applicable regulations, or qualified infection-prevention and sterile-processing oversight.

References

1. Cleaning | Guideline for Disinfection and Sterilization in Healthcare Facilities. Centers for Disease Control and Prevention. 2023-11-28.
2. Effect of Cleaning on Sterilization Efficacy. Centers for Disease Control and Prevention. 2023-11-28.
3. Factors Affecting Quality of Reprocessing. U.S. Food and Drug Administration. 2023-02-14.
4. Reprocessing Medical Devices in Health Care Settings: Validation Methods and Labeling. U.S. Food and Drug Administration. 2025-02-01.
5. Medical instrument reprocessing: current issues with cleaning and cleaning monitoring. PubMed; American Journal of Infection Control. 2019-06-04.

Educational overview. Follow the applicable product instructions, validated procedures, local regulations and your facility’s approved policies.